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Background: In developing the PatientsLikeMe online platform for patients with Multiple Sclerosis (MS), we
required a patient-reported assessment of functional status that was easy to complete and identified disability in
domains other than walking. Existing measures of functional status were inadequate, clinician-reported, focused on
walking, and burdensome to complete. In response, we developed the Multiple Sclerosis Rating Scale (MSRS).
Methods: We adapted a clinician-rated measure, the Guy’s Neurological Disability Scale, to a self-report scale and
deployed it to an online community. As part of our validation process we reviewed discussions between patients,
conducted patient cognitive debriefing, and made minor improvements to form a revised scale (MSRS-R) before
deploying a cross-sectional survey to patients with relapsing-remitting MS (RRMS) on the PatientsLikeMe
platform. The survey included MSRS-R and comparator measures: MSIS-29, PDDS, NARCOMS Performance
Scales, and MSWS-12.
Results: In total, 816 RRMS patients responded (19% response rate). The MSRS-R exhibited high internal
consistency (Cronbach’s alpha = .86). The MSRS-R walking item was highly correlated with alternative walking
measures (PDDS, ρ= .84; MSWS-12, ρ= .83; NARCOMS mobility question, ρ = .86). MSRS-R correlated well with
comparison instruments and differentiated between known groups by PDDS disease stage and relapse burden
in the past two years. Factor analysis suggested a single factor accounting for 51.5% of variance.
Conclusions: The MSRS-R is a concise measure of MS-related functional disability, and may have advantages for
disease measurement over longer and more burdensome instruments that are restricted to a smaller number
of domains or measure quality of life. Studies are underway describing the use of the instrument in contexts
outside our online platform such as clinical practice or trials. The MSRS-R is released for use under creative commons
license.
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Multiple Sclerosis (MS) is a neurological condition char-
acterised by lesions of myelin sheaths encapsulating the
neurons of the brain, spine, and optic nerve, causing
transient or progressive symptoms and disability. Meas-
uring MS is challenging; objective measurement requires
complex tools (e.g. MRI using an expensive and immo-
bile device), experience (e.g. examination from a special-
ist neurologist), and/or significant time to complete (e.g.
MS Functional Composite, 15 minutes of testing requiring* Correspondence: pwicks@patientslikeme.com
PatientsLikeMe Inc, 155 Second Street, Cambridge, MA 02141, USA
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reproduction in any medium, provided the orspecial equipment [1]). Patient-perceived symptoms can
fluctuate seasonally[2], daily, hourly, or even in response
to variations in temperature[3]; they may be unmasked
only on specific tasks, and they may involve complex sys-
tems such as vision, cognition, sexual function, and blad-
der function.
The PatientsLikeMe online data platform (www.
patientslikeme.com) was built to allow patients with life-
changing illnesses to share data about their experiences
of symptoms and disability through structured data col-
lection[4]. Use of the system has shown benefit through
improved health literacy, better communication with
healthcare professionals, and development of a peertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developing other patient-reported outcomes (PROs)
using patients' own language [7,8].
In expanding the platform in 2007 to include MS, a
number of instruments were considered. The MS Impact
Scale (MSIS-29, [9]) was not intended solely to measure
MS disability; it also included health-related functional
impact (e.g. limitations in social and leisure activities).
The MS Walking Scale (MSWS-12) has the obvious limi-
tation of focusing only on walking [10,11]. The North
American Research Committee on Multiple Sclerosis
(NARCOMS) patient registry has developed validated
performance scales (PS) [12,13] in areas including walk-
ing, fatigue, cognition, and vision. The PS have clearly
defined anchor points for each response; but the instru-
ment is long (about 2,500 words), and the inconsistent
response format requires close reading to avoid confu-
sion and erroneous reporting — a potential challenge for
patients with cognitive issues and fatigue. NARCOMS
has also used the patient-determined disease steps
(PDDS) [14], which resembles a patient-reported form of
the Expanded Disability Status Scale (EDSS) and may
have some of the same limitations as that instrument
[15].
In the absence of an agreed-upon “gold standard”
PRO, we collaborated with an MS specialist to develop
the MS Rating Scale (MSRS). This paper describes the
development of the original MSRS, as well as work to re-
vise the scale through cognitive debriefing to produce a
revised version (MRSR-R), data on psychometric per-
formance, and comparisons with other patient-reported
MS scales.
Methods
MS Rating Scale (MSRS) Development
The objective of the MSRS was to accurately quantify
the level of MS-relevant disability experienced by
patients across a range of domains affected by demyelin-
ating lesions. Observation of an MS specialist's clinic at
King's College Hospital in London identified seven
domains routinely asked about in clinical practice as part
of a "top to toe" clinical interview. These domains were
intended to reflect the degree of lesion burden for ner-
vous system regions enervating the region of interest
(e.g. optic nerves for “vision”). We adapted a modified
scoring scheme from the Guy’s Neurological Disability
Scale (GNDS[18]), which took a relatively consistent
approach to scoring each domain, using the first four
levels of disability (“0 - Normal status”, “1 - Symptoms
causing no disability”, “2 - Mild disability not requiring
help from others”, “3 - Moderate disability requiring
help from others”) and the final level (4 - “Total loss
of function, maximal help required”). A consistent
scoring scheme was preferred in order to minimizeresponse burden and encourage repeated entry of data
longitudinally. Total score was the sum of the 7 items,
with a range of 0–28. For website display the patient
profile rescales the score to a 0–100 scale (Figure 1).
Remaining domains from the GNDS, such as “mood”
(split into anxiety and depression), bladder, bowel, sex-
ual dysfunction, fatigue and spasms, were integrated
into the existing PatientsLikeMe symptoms system and
rated by patients as “none”(0), “mild” (1), “moderate” (2),
or “severe” (3).
The resulting scale, the MSRS, was felt to have the ad-
vantage of tapping a range of important domains for MS
patients, not solely focused on walking but including
other aspects of function that might be important to
monitor over time. Using the MSRS, patients are easily
able to create a longitudinal record of their experience of
MS to share with others and to help understand the im-
pact of their treatments (Figure 1). At the time of survey
invitation (Fall 2010), 15,219 users had completed at
least one MSRS survey, for a total of 72,975 reports on
the PatientsLikeMe system. Members join the site under-
standing that their de-identified data will be used for re-
search as part of the terms of service.
Review and Revision of the MSRS
Cognitive Interviews
To test that the instrument captured all domains con-
sidered relevant by patients and to identify areas for
improvement, patients were recruited for interview by
private message on the PatientsLikeMe platform. All
patients were local to Boston, Massachusetts and were
selected to represent diverse clinical experience. Patients
were offered a $50 honorarium for their participation,
which took approximately 2 hours. Feedback served as
the basis for a revised MSRS (MSRS revised, MSRS-R).
The wording of MSRS response options was clarified,
defining “disability” more clearly and changing the high-
est response category from “total” to “severe” disability,
along with minor text changes. (see Table 1 for revi-
sions). The domain “upper limb function” was clarified
to ”using your arms and hands”, and “bowel or bladder”
dysfunction was added as a domain of functional impair-
ment (see Table 2 for revisions).
Online survey
The PatientsLikeMe survey system was used to test the
psychometric properties of the MSRS-R (incorporating
feedback from the cognitive debriefings). The survey
consisted of the MSRS-R, a fixed list of MS symptoms,
and a report about the patient's most recent relapse. If
they chose to report on that relapse, they were asked for
start- and end-dates of the relapse, to rate the severity of
the relapse (“mild”, “moderate”, or “severe”), and whether
the relapse had required hospitalization or treatment
Figure 1 Profile of a sample MS patient featuring rich data and history. Written informed consent was obtained from the patient for
publication of this report and any accompanying images.
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tion. The patient then used the MSRS-R to describe their
level of disability when they were feeling worst during
the relapse.
The remaining sections of the survey were composed
of scales identified as being used as secondary outcome
measures in clinical trials: the MSIS-29, NARCOMS PS,
PDDS, and MSWS-12. Quality-of-life instruments such
as the MSQOL-54 were not used because of their pre-
dominant focus on QOL as opposed to disability. ThePRIMUS consists of 3 components – 22 symptoms, 15
activities, and 22 quality-of-life statements. We made an
error in implementing the quality-of-life component and
included only the first 12 items, but fortunately these
items sample the full range of item locations on the
quality-of-life scale, as described by the PRIMUS develo-
pers[16]]. Those who had completed the survey within
one week of initial invitation were asked to complete a
1-week retest, which included only the PatientsLikeMe
measures. For this follow-up survey the patients were
Table 1 Original and revised MSRS anchor points
Original MS Rating Scale (MSRS) MSRS, Revised (MSRS-R)
No Symptoms - No symptoms or disability in this specific area No Symptoms - No symptoms or disability in this specific area
None - Aware of symptoms but no functional disability Some Symptoms, No Disability - Aware of symptoms but no
limits on my activities
Mild - Mild disability but not requiring help from others Mild Disability - Mild limits on my activities, but I do not need
help from others or use other aids
Moderate - Moderate disability that requires some help from others Moderate Disability - Moderate limits on my activities,
and I sometimes need help from others or use other aids
Total Disability - Total disability and help always required Severe Disability - Severe limits on my activities, and I usually
need help from others or use other aids
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feeling at the time of the first survey. Another instru-
ment, the PRIMUS, was also administered but is not
reported here due to the instrument being fielded
incorrectly.
Upon site registration, PatientsLikeMe users agree that
they may be asked to participate in research; as a
research study using only online questionnaires with
minimal risk, IRB approval was not sought for this study.
However, in accordance with the Declaration of Helsinki,
participants were informed about the aims of the study,
were given the option to opt-in without incentive and
opt-out without any negative consequences. In order to
target active users, we invited patients accessing their
accounts during the 90 days prior to 24 August 2010.
Five days after the initial invitation, a reminder was sent
to all invited patients who had not yet completed the sur-
vey. At that point an invitation to the retest was also sent
to all who had completed the baseline survey within the
first six days of the field period. Retest participants also
received a reminder 5 days after the retest invitation.Statistical Analysis
Data were analyzed using Statistical Package for the
Social Sciences (SPSS) V20. Descriptive statistics documentTable 2 Original and revised MSRS items




Upper Limb Function Using your arms and hands




Thinking/Memory/Cognition Thinking, Memory, or Cognition
Sensation/Burning/Pain Numbness, Tingling, Burning Sensation
or Pain
n/a Bowel or bladderthe distribution of responses and measurement properties
of the MSRS-R. Principal component analysis was used to
identify the structure of the MSRS-R. The number of fac-
tors was left unconstrained, with eigenvalues >1 initially
considered worthy of further interest. We also conducted a
parallel analysis, using the procedure of Horn [19] and SPSS
syntax [20], in order to compare the magnitude of observed
eigenvalues against that generated by random arrangements
of the same data.
Internal consistency was assessed using item-to-item
Spearman correlations and Cronbach’s alpha, which
should be above 0.7 to be considered adequate. Concur-
rent validity was tested using correlations between the
MSRS-R and other scales, in addition to subscales of the
MSIS-29, MSWS-12, and PRIMUS. Test-retest reliability
was assessed first with Spearman correlations and then
with a Bland-Altman plot.
Known-group validity was assessed by comparing the
MSRS-R scores of patients grouped by level of impair-
ment on the self-reported PDDS, which is known to
correlate highly with the EDSS, a widely used clinician-
rated scale in MS trials. In addition, we used the patient’s
estimate of the number of relapses they had experienced
in the past two years, on the basis that relapses in relapsing-
remitting MS contribute to a worsening burden of disability
[21]. ANOVA (with Bonferroni corrected post-hoc tests)
was used to compare MSRS-R scores in the groups, and it
was hypothesized that patients in more severe PDDS groups
or with a higher number of relapses in the past two years
would have worse (higher) MSRS-R scores. Given the
prominence of walking measurements in MS, we also per-
formed similar analyses for the MSRS-R walking item.
Other between-group differences were assessed using
ANOVA, Student’s t-test, and Kruskal-Wallis tests as ap-
propriate. Clinician-assessed validity and responsiveness to
change are the subjects of future investigations.Results
Responder characteristics
Data reported here describe patients who self-reported a
diagnosis of relapsing-remitting MS (RRMS), but data
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reported here). The main survey was launched on 8
September 2010. 4,382 invitations were issued to RRMS
patients; complete responses were received from 816
RRMS patients (18.6%); incomplete responses were
received from 156 patients (3.6%, only complete responses
are described here), and opt-outs from 121 (2.8%). The
remaining 3,289 (75.1%) of patients made no response to
the survey invitation.
All prospective members of the site are invited to add
their age and sex to their profile, but not all had chosen
to do so by the time of survey. Using available profile
data from non-completers, patients who completed
the baseline survey were around 3 years older than non-
completers (see Table 3). The groups differed sig-
nificantly on sex, although this difference became a
non-significant trend after removing patients without
ascertained sex (X2(1) = 3.476, p = .063). Baseline com-
pletes were also more likely to have reported more
relapses on their profile in the 2 years prior to the sur-
vey, but this may represent different levels of engage-
ment on the website rather than true disease severity; a
similar explanation may underlie for the similar pattern
for most recent MSRS score from the patients’ profiles.
A little over half of patients reported a recent relapse
(52%, N= 424/816). Duration since relapse was distribu-
ted between 33% (N= 140/424) reporting one within the
month prior to survey completion, 23% (N= 97/424)
reported a relapse between one and three months prior,
and 44% (N= 187/424) reporting a relapse three or more
months ago. The vast majority of relapses (98.7%) were
reported from the past decade (2000–2010).
On 14 September, invitations for the 1-week retest
were sent to the 391 patients who had completed the
survey by this point. 192 RRMS patients (49.1%) com-
pleted the retest survey; 27 (6.9%) provided incomplete
answers, and 10 (2.6%) opted out at this stage. The
remaining 162 (41.4%) made no response to the retest
survey invitation. Participants who completed the retest
did not differ on sex, age, disease duration, or disease
severity from other eligible participants who took the
baseline survey (Table 3), or from those who had not
completed the baseline survey in time to be eligible for
the retest (not shown). Both surveys were closed to fur-
ther participation on 23 September 2010.
MSRS-R Psychometric Characteristics
The revised MSRS-R measure added “bowel or bladder”
as a functional area. The revised measure also character-
ized levels of impairment using more patient-friendly
terms around “activity limitation” in contrast to “func-
tional disability”, and characterized the most disabled
state as “severe” rather than “total disability”. Although
we did not design the study to compare severity ofdisability using the original MSRS and the MSRS-R, we
did have a small number of respondents (n = 211) who
had used the original MSRS to populate their site profile
within a month of completing the baseline MSRS-R for
this study. Table 4 shows somewhat greater use of the
extreme disability category (“severe”) for the MSRS-R
compared with the extreme disability category (“total
disability”) for the original MSRS.
Factor analysis
We assessed the dataset for suitability for factor analysis.
Given the baseline respondent sample size of 816, we
had approximately 103 participants per variable. Correla-
tions between items were all above ρ= 0.3. Bartlett’s test
of sphericity[22] was significant at p< 0.001, supporting
the factorability of the correlation matrix. The Keyser-
Meyer-Olkin value of sampling adequacy was 0.884,
exceeding the recommended value of 0.6[23,24]. PCA
revealed a single factor with an eigenvalue of 4.2
accounting for 51.5% of variance; the second highest
eigenvalue was 0.9. Further, the results of a parallel ana-
lysis[19] using the same dataset showed no components
exceeding the corresponding criterion values (8 variables
x 816 respondents x 100 replications); the highest eigen-
value produced by the parallel analysis was 2.0. Table 5
shows the MSRS-R item factor loadings.
Scale characteristics
Mean MSRS-R score was 10.9 (SD: 6.1) with a median of
10.0 (IQR: 6–15). Only 0.7% of patients scored at floor
(MSRS= 0), and no patients scored at ceiling (0%,
MSRS= 32.) Table 6 shows the distribution of item
scores; walking (66.1%) and sensory aspects (60.2%) were
the domains most frequently associated with some level
of disability; speech (21.5%) and swallowing (16.6%) were
the least frequently affected.
Internal consistency
Cronbach’s alpha (.86) indicated acceptable internal
consistency. Item convergent validity as assessed by cor-
relations between items and total score was also accept-
able, ranging from Spearman’s rho of ρ= 0.68 for walking
to ρ= 0.77 for using arms and hands.
Test-retest
A Bland-Altman plot of the differences in total score at
baseline and 1-week retest (N = 192) showed no system-
atic pattern and no outliers (see Figure 2). The plot
showed 182 of 192 cases (95%) lie within two standard
deviations of the mean (mean difference = 0.74, SD: 2.7,
Limits of agreement (+/− 2SD): -4.6 – 6.1). Examina-
tion of item-level differences using a Wilcoxon signed
rank test revealed significant differences only for the
“Numbness, Tingling, Burning Sensation, or Pain” item
Table 3 Description of patient samples including completes and non-completes
Baseline (4,382 eligible) 1-Week Retest (391 eligible)
Non-Completes Completes Sig. Non-Completes Completes Sig.
N of cases 3566 816 199 192
Sex
Female (%) 2715 (76.1) 619 (75.9) X2 = 15.25 151 (75.9) 144 (75.0) X2 = 2.22
Male (%) 622 (17.4) 170 (20.8) df = 2 42 (21.1) 46 (24.0) df = 2
Not ascertained (%) 229 (6.4) 27 (3.3) p< .001 5 (2.0) 2 (1.0) p = .329
Age in years
Mean (SD) 42.9 (9.9) 45.9 (9.8) t = 7.61 45.5 (9.9) 46.5 (9.5) t = .989
Median (IQR) 43.0 (36–50) 47.0 (39–53) df = 4,102 45.0 (38–53) 46.0 (40–53) df = 377
Range 15 - 81 19 - 73 p< 0.001 19 – 73 21 - 67 p= .323
Not ascertained (%) 251 (7.0) 27 (3.3) 9 (4.5) 3 (1.6)
Years since MS diagnosis
Mean (SD) 6.5 (6.2) 6.6 (6.6) t = .79 5.7 (7.7) 6.7 (6.3) t =−.106
Median (IQR) 4.0 (2–9) 4.0 (2–9) df = 4,326 4.0 (2–9) 5.0 (2–9.8) df = 388
Range 0 - 39 0 - 52 p = .430 0 - 52 0 - 37 p= .916
Not ascertained (%) 50 (1.4) 4 (0.5) 1 (0.5%) 0 (0.0)
Number (%) of reported relapses in previous 2 years
0 2440 (68.4) 471 (57.7) X2 = 53.82 119 (59.8) 108 (56.2) X2 = 6.14
1 719 (20.2) 182 (22.3) df = 4 45 (22.5) 44 (22.9) df = 4
2 216 (6.1) 85 (10.4) p< 0.001 20 (10.1) 15 (7.8) p = .189
3 106 (3.0) 35 (4.3) 5 (2.5) 15 (7.8)
4 or more 85 (2.4) 43 (5.3) 10 (5.0) 10 (5.2)
PDDS group (%)
normal n/a 189 (23.2) n/a 46 (23.1) 42 (21.9) X2 = 4.55
mild disability n/a 107 (13.1) 26 (13.1) 26 (13.5) df = 4
moderate or gait disability n/a 242 (29.7) 60 (30.2) 46 (24.0) p = .225
early cane n/a 143 (17.5) 35 (17.6) 32 (16.7)
late cane, bilateral support, wheelchair, or bedridden n/a 135 (16.5) 32 (16.1) 46 (24.0)
Most recently entered profile MSRS (%)
not ascertained 314 (8.8) 25 (3.1) X2 = 47.515 11 (5.5) 1 (0.5) X2 = 10.24
0 to 9 341 (9.6) 84 (10.3) df = 7 24 (12.1) 25 (13.0) df = 7
10 to 19 511 (14.3) 126 (15.4) p< 0.001 23 (11.6) 31 (16.1) p = .175
20 to 29 544 (15.3) 131 (16.1) 28 (14.1) 28 (14.6)
30 to 39 677 (19.0) 132 (16.2) 33 (16.6) 33 (17.2)
40 to 49 413 (11.6) 87 (10.7) 20 (10.1) 16 (8.3)
50 to 59 417 (11.7) 134 (16.4) 33 (16.6) 35 (18.2)
60 or higher 97 (11.9) 97 (11.9) 27 (13.6) 23 (12.0)
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and mean difference of 1.6 points (SD: 1.1).
Concurrent validity
The MSRS-R total score was correlated significantly
(p< 0.001) with all comparable measures using Spearman’s
rho: MSIS-29 physical subscale (ρ= .74), MSWS-12(ρ= .66), PDDS (ρ= .62), MSIS-29 psychological subscale
(ρ= .60). MSRS-R total scores with the NARCOMS PS var-
ied from ρ= .44 for depression to ρ= .63 for cognitive; but
as the NARCOMS PS do not produce a total score, an
item-by-item analysis was performed. Table 7 shows the
correlations between MSRS-R domains and NARCOMS
PDDS and PS item scores; correlations were highest for
Table 4 Proportion of patients in most extreme disability
category in original (MSRS) and revised (MSRS-R) scales
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tween MSRS-R domains and their relevant PS item scores
around ρ= .7, indicating good agreement.
Known group validity
We hypothesized that higher total MSRS-R scores
(worse disability) would be observed for those with wor-
sening PDDS status and a higher number of relapses.
Between-groups differences on MSRS-R by PDDS
levels were found to be significant using ANOVA
(F(7,808) = 77.250, p< .001). Post-hoc Bonferroni tests of
all pair-wise comparisons revealed significant differences
between MSRS-R for normal and mild PDDS from all
other PDDS levels (p< .001). “Moderate” and “Gait dis-
ability” PDDS levels were not significantly different from
one another (p> 0.05). Higher levels of mobility impair-
ment (“early cane”, “late cane”, “bilateral support”) dif-
fered significantly from “normal”, “mild”, and “moderate”
disability, but not from each other (p> 0.05). “Use of
a wheelchair or scooter” differed only from “normal” or
“mild” disability (p< 0.05) on the MSRS-R. No respon-
dents endorsed the most severe category on the PDDS
(“Bedridden”). Examination of individual MSRS-R items
revealed a much stronger step-wise relationship betweenTable 5 Principal component analysis item loadings for a




Using your arms and hands .770
Vision (with glasses or contacts if you use them) .708
Speaking clearly .751
Swallowing .737
Bowel or bladder .662
Thinking, memory, or cognition .739
Numbness, tingling, burning sensation, or pain .723PDDS and the MSRS-R walking item than other items,
although “bladder & bowel” shows a similar, though less
marked pattern (Table 8).
Our second known group comparison consisted of
comparing MSRS-R scores against the number of self-
reported MS relapses on patients’ profiles for the two
years preceding the survey (Table 9). One-way ANOVA
showed significant differences for total MSRS-R score
(F(4,811) = 6.422, p< 0.001). Two post-hoc Bonferroni
tests were significant: between “no relapses reported”
and “4 or more” (mean difference: 4.3, 95% CI: 1.6-6.9,
p< 0.001) and between “1 relapse” and “4 or more”
(mean difference: 3.3, 95% CI: 0.5-6.1, p< 0.001). We
also checked whether PDDS were significantly different
across recent burden of relapses using a Kruskal-Wallis
test and found no significant difference (X2(4) = 5.093,
p = .278).
MSRS-R in retrospectively reported relapses
Within MSRS-R scores for retrospectively reported
relapses captured actively in the survey (as opposed to
passively in the patient’s site profile), Figure 3 shows the
difference between MSRS-R at baseline and most recent
relapse according to the perceived severity of the relapse
(“mild”, “moderate”, or “severe”, N = 424). The largest
differences were reported, on average, for walking, upper
limb function, and the sensations (numbness, tingling,
burning, and pain), followed by vision, speaking, and
then swallowing.
Discussion
The original MSRS was designed to minimize respond-
ent burden, using a minimum number of items to cover
relevant aspects of patient experience and simple, clear
language in both the questions and response options.
Patients have indicated in qualitative interviews that the
questions are relevant to their experience, easy to under-
stand, and easy to respond to, and provide an accurate
profile of their experience of MS over time. Its deploy-
ment on PatientsLikeMe led to widespread use by thou-
sands of MS patients, who report that using the site has
produced a number of benefits including improved
understanding of their condition and improved commu-
nication with their healthcare providers[5]. Following
cognitive debriefing, a number of small modifications
were made to produce the MSRS-R (Revised). After
fielding in a survey, statistical analysis shows the MSRS-
R exhibits desirable psychometric properties in terms of
ceiling and floor effects, internal consistency, factor
structure, test-retest, and known-group validity. Import-
antly, the MSRS-R correlated in expected ways with
alternative measures in widespread use (MSIS-29, PDDS,
NARCOMS PS, and MSWS-12), suggesting acceptable
concurrent validity and potential use as a research tool.
Table 6 MSRS-R item distributions
Current MSRS-R (N=816) No Symptoms Some symptoms, No Disability Mild Disability Moderate Disability Severe Disability
No symptoms or disability
in this specific area
Aware of symptoms but no
limits on my activities
Mild limits on my activities,
but I do not need help from
others or use other aids
Moderate limits on my activities
and I sometimes need help from
others or use other aids
Severe limits on my activities
and I usually need help from
others or use other aids
Walking 12.4% 21.6% 24.4% 33.7% 8.0%
Using your arms and hands 26.8% 33.5% 25.4% 13.5% 0.9%
Vision (with glasses or
contacts if you use them)
35.0% 31.0% 19.2% 12.7% 2.0%
Speaking Clearly 47.2% 31.3% 15.8% 5.6% 0.1%
Swallowing 55.6% 27.7% 12.6% 3.9% 0.1%
Bowel or bladder 25.5% 27.7% 26.3% 16.4% 4.0%
Thinking, Memory, or Cognition 16.7% 32.5% 26.7% 19.9% 4.3%
Numbness, Tingling,
Burning Sensation or Pain
























Figure 2 Bland-Altman plot for baseline and 1-week retest MSRS-R.
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than any of the other instruments fielded in this study;
for instance, the PDDS requires a patient to read appro-
ximately 360 written words to gauge walking disability;
the MSRS-R walking item has 33 words and produces
very similar results. Furthermore, our analysis confirmed
that the PDDS, like the EDSS it is based upon, is pre-
dominantly focused on walking; by contrast, the entire
MSRS-R covers eight domains but is only 53 words long
and uses a consistent response format, which makes it
less burdensome for patients to read and complete.Table 7 Correlations (Spearman’s rho) between MSRS-R doma
(p< 0.001)
MSRS-R Domains PDDS Mobility Hand Vision Fatigue
Walking 0.84 0.84 0.43 0.25 0.44
Using your arms and hands 0.48 0.47 0.70 0.38 0.48
Vision (with glasses or contacts
if you use them)
0.28 0.28 0.35 0.71 0.35
Speaking Clearly 0.28 0.27 0.42 0.38 0.37
Swallowing 0.32 0.32 0.39 0.36 0.39
Bowel or bladder 0.48 0.46 0.30 0.30 0.37
Thinking, Memory, or Cognition 0.28 0.26 0.37 0.41 0.49
Numbness, Tingling, Burning
Sensation or Pain
0.45 0.42 0.48 0.36 0.51Currently, MS trial design focuses on the frequency of
relapses but is uninformed by the nature of these
relapses, and so an attack that leaves one patient unable
to walk and another unable to see are counted the same.
Analysis of retrospective relapses in the current study
demonstrated that the nature of relapses experienced in
this population could be characterized by changes from
baseline within specific domains of function using the
MSRS-R. This may be useful in improving our under-
standing of MS characterization, progression, and response




Sensory Spasticity Pain Depression Tremor
0.27 0.44 0.41 0.55 0.40 0.25 0.53
0.44 0.28 0.56 0.50 0.50 0.32 0.49
0.42 0.26 0.36 0.32 0.40 0.32 0.32
0.47 0.23 0.32 0.28 0.36 0.27 0.35
0.43 0.30 0.38 0.33 0.39 0.30 0.35
0.34 0.71 0.35 0.36 0.32 0.25 0.36
0.77 0.28 0.38 0.34 0.44 0.42 0.42
0.45 0.31 0.72 0.53 0.67 0.38 0.47
Table 8 Comparison of MSRS-R and MSRS-R items by known PDDS groups




























0 - normal 189 4.9 0.7 0.5 0.6 0.3 0.2 0.7 1.0 1.1
(3.5) (0.7) (0.7) (0.8) (0.5) (0.5) (0.8) (0.8) (0.8)
1 - mild disability 107 8.8 1.4 0.9 0.9 0.7 0.5 1.2 1.5 1.6
(4.5) (7.5) (0.8) (0.9) (0.8) (0.8) (1.0) (1.0) (1.0)
2 - moderate 99 11.8 1.8 1.4 1.5 1.0 0.6 1.4 2.0 2.0
(4.2) (0.8) (0.8) (1.1) (0.9) (0.8) (1.0) (1.0) (1.0)
3 - gait disability 143 12.3 2.4 1.6 1.3 0.9 0.8 1.5 1.8 2.1
(4.8) (0.6) (1.0) (1.0) (0.9) (0.8) (1.0) (1.1) (1.0)
4 - early cane 143 14.1 2.9 1.6 1.4 1.0 0.9 2.0 1.9 2.4
(5.7) (0.5) (1.0) (1.1) (1.0) (0.9) (1.1) (1.1) (1.1)
5 - late cane 90 15.9 3.3 2.0 1.7 1.2 1.1 2.0 2.0 2.6
(5.3) (0.5) (0.9) (1.3) (1.0) (1.0) (1.0) (1.2) (1.1)
6 - bilateral support 31 15.5 3.5 1.9 1.4 1.0 0.9 2.7 1.8 2.4
(5.4) (0.5) (1.1) (1.1) (1.0) (1.1) (1.0) (1.0) (1.2)
7- wheelchair or scooter 14 13.4 3.9 1.4 1.0 0.9 0.9 2.3 1.2 2.1
(5.5) (0.4) (1.3) (0.3) (1.1) (1.0) (1.2) (1.2) (1.7)
8 - bedridden 0 n/a n/a n/a n/a n/a n/a n/a n/a n/a
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cumulative burden of disability resulting from recurrent
relapses than the PDDS; further study could compare
MSRS-R against other measures of cumulative burden such
as magnetic resonance imaging.
Following this psychometric validation and upgrade of
the existing MSRS to the newer MSRS-R, passively col-
lected profile data in the PatientsLikeMe platform could
be studied as a form of observational registry combining
demographic, social networking, treatment, and symp-
tom data. Such data would extend to a larger number of
patients than described here, and to MS disease types
other than RRMS, and could illuminate the real-world
impact of newer therapies for MS. For instance, it may
be particularly interesting to retrieve the prospective data
for patients who did not report any treatment at the timeTable 9 Comparison of MSRS-R by number of MS relapses
reported on profile in the past two years




0 (none reported) 471 10.2 (5.8)
1 182 11.2 (5.9)
2 85 11.9 (6.3)
3 35 12.0 (6.7)
4 or more 43 14.5 (7.1)of creating their account and study the amount of
MSRS-R change that triggers initiation of treatment, or
to gauge the effectiveness of treatment in stabilizing or
reducing disability relative to similar patients who did
not start treatment.
With regard to administration, although we did not
explicitly test for differences between, e.g., paper-and-
pencil questionnaires compared with online question-
naires, we expect that there would be no or minimal
difference between data collected in these modes. The
cognitive interviews did not suggest any significant differ-
ence between patients’ responses on paper and how they
would have responded (or how they had responded previ-
ously) using the report tools on the PatientsLikeMe plat-
form. The online form is two-dimensional, and no
wording or format changes are required to adapt the
MSRS-R, symptoms, or relapse questions for paper-and-
pencil administration.
The limitations of this study are shared by many postal
or internet-based questionnaire designs. We have no
independent validation that respondents actually do have
MS; however, as there was no incentive for participating,
there would be little incentive to enter false data. Our
analysis of responders found them to be a little older and
more affected by MS than non-respondents; this is per-
haps unsurprising given that sicker patients may be more
inclined to return to PatientsLikeMe to seek support. One
Figure 3 Spider plot of MSRS-R domain differences between baseline MSRS-R score and ‘most recent’ relapse, broken out by severity.
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tematically describe the population of non-responders.
It is likely that the entire PatientsLikeMe population
may differ systematically from the broader MS popula-
tion (see [8] for a comparison with the Sonya Slifka Lon-
gitudinal MS Study), therefore these findings should be
generalized cautiously. That said, our findings on the re-
sponse characteristics of the comparison instruments
used proved similar to their own validation studies. The
response rate (19%) was relatively low but was not atyp-
ical for a survey of this online community[5]. The most
significant limitation was that we lacked independent
clinical assessment of disease severity from a clinician
experienced in the field; we are seeking to address this in
future studies.
A further limitation that underscores the difference be-
tween passively collected profile data and actively sampled
survey data is the mismatch between the 345 completers
(43%) who had at least one relapse recorded on their profile
and the 424 completers (52%) who reported having at least
one relapse when polled on the survey. Passively collected
data provides a large body of longitudinal data but suffers
from attrition bias; actively collected data provides a more
accurate cross-section at one or a few points in time but is
more costly to collect and may suffer from responder bias.
Evaluating the quality of the test-retest with a Bland-
Altman plot is difficult in the absence of a gold standardand the lack of agreed standards for measurement vari-
ability in MS. It is possible that in performing the test-
retest, some patients may not have clearly read the
instructions to report retrospectively to the first time
they completed the survey; if so, the degree of test-retest
agreement reported here would be an underestimate and
should be investigated further.
A copy of the MSRS-R is included as an appendix to
this manuscript, and the instrument is distributed with a
Creative Commons “Attribution-ShareAlike3.0 Unported”
license, meaning it can be used freely (including commer-
cially), altered, transformed, or built upon, so long as all
derivative work is licensed in the same fashion and proper
attribution is made (Additional file 1).
Conclusion
The MSRS-R has been shown to be a useful tool for
measuring the impact of MS and may help patients and
clinicians understand the course of disease, the impact of
their treatments, side effects, and relapses. It is hoped
that an enhanced understanding of these aspects of MS
may help improve patients' outcomes.
Additional file
Additional file 1: Multiple Sclerosis Rating Scale (Revised): MSRS-R [25].
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